Arthneeti
All Q2 FY26 results →
AT

Axsome Therapeutics, Inc.

Q2 FY26Pharmaceuticals

Axsome Therapeutics, Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹233
Market cap₹12.0K Cr
P/E39.8
Updated30 May 2026
Read3 min read

What the Q2 FY26 call signalled

2 of 3 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned

The short version

- AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from Major Depressive Disorder (MDD) and Alzheimer’s disease (AD) agitation indications. - Focus currently remains on revenue growth as the top priority.

From Axsome Therapeutics, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.

Revenue & Sales Performance

Good growth
  • AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from Major Depressive Disorder (MDD) and Alzheimer’s disease (AD) agitation indications.
  • Continued growth expected for AUVELITY driven by expanded sales force (~630 reps) targeting 68,000 HCPs across multiple specialties and care settings.
  • Anticipated strong uptake from ongoing awareness campaigns, improved payer coverage (86% total coverage), and early frontline prescribing shifts.
  • SUNOSI revenue growing steadily, with 16% year-over-year growth in Q1 2026 and stable payer coverage (~83%).
  • SYMBRAVO showing 36% growth compared to Q4 2025, with sales force expansion and increasing primary care use.

2 more points from Axsome Therapeutics, Inc.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Axsome Therapeutics, Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • The company is primarily focused on commercial execution, including expanding their sales force and marketing activities (e.g., AUVELITY and SYMBRAVO launches).
  • Investment efforts appear directed towards clinical development with several Phase III trials planned or ongoing (e.g., AXS-12, AXS-05, Solriamfetol programs, AXS-20 in late-stage development).
  • Acquisition history noted (e.g., SUNOSI acquisition), but current focus remains on pipeline and commercialization rather than new acquisitions.

2 more points from Axsome Therapeutics, Inc.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Axsome Therapeutics, Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Axsome Therapeutics, Inc. said on order book & pipeline — free account, 30 seconds.

Continue your research

Others in Pharmaceuticals this season

  • Elanco Animal Health Incorporated (Q2 FY26)

    Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S

  • Jazz Pharmaceuticals plc (Q2 FY26)

    Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo

  • Viatris Inc. (Q2 FY26)

    Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7

  • Royalty Pharma plc (Q2 FY26)

    Royalty Pharma plc Q2 FY26 quarterly results analysis. Royalty Pharma expects strong low-volatility top and bottom line growth through 2030 and beyond, driven b

Compare:vs AstraZeneca PLCvs Johnson & Johnsonvs Novartis AG

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Axsome Therapeutics, Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Axsome Therapeutics, Inc. Q2 FY26 results?

- AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from Major Depressive Disorder (MDD) and Alzheimer’s disease (AD) agitation indications. - Focus currently remains on revenue growth as the top priority.

What is Axsome Therapeutics, Inc. share price analysis?

Axsome Therapeutics, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 39.8 with a market cap of $11,981. Investors should review the full earnings analysis for detailed insights.

Keep Axsome Therapeutics, Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.